Fact-checked by Grok 2 weeks ago

Phibro


Phibro LLC is a global physical commodities trading firm headquartered in , specializing in the merchant investment and optimization of , metals, and agricultural products, with a contemporary emphasis on low-carbon and renewable assets such as used cooking oil and recovered from tires. Originally founded in 1901 as Philipp Brothers by Julius Philipp in , , the company expanded internationally with offices in (1909) and (1915), initially focusing on metals and chemicals trading before evolving into a pioneer of modern oil markets during the crises, where it generated substantial profits amid volatile crude prices. Key milestones include its 1981 acquisition of investment bank for $550 million, forming Phibro-Salomon Inc., and subsequent mergers with Minerals and Chemicals in 1967 and integration into via the 1998 Travelers merger, followed by sale to in 2009 and privatization in 2016 under Energy Arbitrage Partners led by former executive Simon Greenshields. Phibro's defining characteristics encompass entrepreneurial risk-taking in physical trading, contributions to global price transparency and liquidity, and a legacy of high-stakes operations that included becoming the largest independent U.S. oil refiner by 1988, though it faced challenges such as the 2014 closure of its U.S. trading unit amid regulatory scrutiny over .

Company Overview

Profile and Operations

Phibro Animal Health Corporation (: PAHC) is a diversified animal health and mineral nutrition company headquartered in . Incorporated in 1946, the company went public in 2014 through an that raised approximately $125 million in gross proceeds for the firm. With around 2,475 employees, Phibro focuses on developing, manufacturing, and marketing solutions to support livestock producers worldwide. The company serves the animal health needs of , , , and sectors through medicated feed additives, nutritional supplements, and . Operating in over 80 countries, Phibro markets approximately 750 product lines to about 4,200 customers, emphasizing in animal to meet global protein demands. Phibro structures its operations into two primary segments: Animal Health, encompassing antibacterials and anticoccidials for disease prevention, and Mineral Nutrition, providing supplements to optimize animal performance and health. Its stated purpose centers on advancing animal health to enhance the and of systems.

Core Business Segments

Phibro Animal Health Corporation operates primarily through its Animal Health and Mineral Nutrition segments, which together form the core of its revenue-generating activities focused on production. The Animal Health segment emphasizes disease prevention and control in , , and via medicated feed additives, including ionophores such as Coxistac®, Aviax®, and Posistac® for combating in . This segment also includes antibiotics like Mecadox® (carbadox), approved for over 50 years in the U.S. to control and improve gut health in growing pigs. These products are supplied to integrated producers, operations, and farms, often through feed mills that incorporate them into rations for systems. The Mineral Nutrition segment provides premixes and trace mineral supplements, such as GemStone®, Vistore®, and Phil-Chrome®, formulated to correct deficiencies in essential elements like copper, manganese, zinc, and selenium across species. These offerings target ruminants, including dairy and beef cattle, as well as monogastrics like poultry and swine, enhancing immune function and overall health without claims of direct growth promotion, in line with regulatory constraints on nutritional supplements. Custom blends are developed to meet specific nutritional needs, preserving feed efficiency in high-density production environments. Phibro employs a sales model, distributing products directly to veterinarians, farmers, and agribusinesses via local offices or intermediaries like feed manufacturers, prioritizing cost-effective solutions for disease management and nutritional balance in intensive . Primary markets include the , , and , where demand for these segments supports large-scale livestock operations.

Historical Development

Origins and Chemical Roots (1946–1973)

Philipp Brothers Chemicals, Inc. was established in 1946 by Bendheim, who separated the chemical operations from the broader Philipp Brothers metals trading entity to form this independent firm. The company's roots extended to the family's raw materials trading activities, initiated by Julius Philipp in , , in 1901 and continued in through Philipp Brothers, Inc., founded by Bendheim in 1914 after his immigration. Initially headquartered in , the firm capitalized on postwar demand for industrial inputs, positioning itself as a trader in without initial involvement in , repackaging, or processing. Early operations centered on the , marketing, and distribution of metals, minerals, and basic industrial chemicals, serving sectors such as and processing industries. Subsidiaries handled regional distribution, for instance, in and , where activities involved straightforward sales of imported chemicals to end-users without value-added alterations. This trading model drew on the Philipp family's longstanding expertise in metal ores and concentrates, enabling efficient supply chains amid expanding networks post-World War II. By the late , Philipp Brothers Chemicals had solidified its role in the chemicals market, though it remained distinct from the metals-focused Philipp Brothers, which grew into the world's largest metal trader during this era. The firm's emphasis on commodity-grade products—such as inorganic chemicals and mineral derivatives—fostered knowledge in formulation stability and sourcing reliability, foundational for future diversification, while adhering to a non-manufacturing structure that prioritized volume trading over product innovation. No animal health applications emerged in this period, with activities confined to industrial applications.

Transition to Animal Health (1974–2002)

In 1974, Philipp Brothers Chemicals, Inc. (later ) acquired Koffolk, an company focused on animal nutrition, initiating its shift from industrial chemicals toward medicated animal feeds and coccidiostats to address efficiency needs in production. This move capitalized on emerging demands for feed additives that improved growth rates and disease control in and , driven by post-World War II expansions in global . By 1980, Phibro had acquired assets to establish its U.S. animal nutrition operations through Agri Products, broadening its in nutritional supplements and antibacterials tailored to and species. Throughout the and , the company expanded production of antibacterial feed additives and specialties like trace minerals, aligning with surging global output—poultry production alone doubled worldwide between 1980 and 2000—to support denser, more productive herds and flocks. Internal research and development efforts during this era introduced proprietary supplements for function and mineral nutrition, enhancing feed conversion without relying heavily on external partnerships. In 1994, Phibro commenced manufacturing of , a antagonist used as a to prevent parasitic infections in , further solidifying its role in preventive animal health. By 2000, the acquisition of Pfizer's medicated feed additives integrated advanced antibacterials like virginiamycin, boosting Phibro's capacity to supply large-scale integrators with products proven to reduce mortality and optimize in commercial operations. These developments positioned Phibro as a specialized provider of performance-enhancing solutions, grounded in empirical improvements to feed efficiency amid mechanized agriculture's scale-up, prior to broader consolidations in the sector.

Acquisitions and Modern Expansion (2003–Present)

In 2003, following the 2000 acquisition of Inc.'s global medicated feed additives business, which significantly expanded its portfolio in animal prevention and , the company rebranded as Phibro Animal Health Corporation to emphasize its focus on animal health solutions. This strategic shift supported growth in medicated feed additives for , , and , enhancing capabilities in managing bacterial infections and nutritional deficiencies in food animals. Subsequent expansions included the 2009 acquisitions of Baltzell, a U.S.-based business, and ABIC Laboratories, an Israel-based producer, which bolstered supplementation and offerings for and control. The 2010s marked further diversification through targeted acquisitions enhancing non- alternatives and specialized amid evolving regulatory pressures on use. In 2011 and 2012, Phibro acquired the Animate and OmniGen-AF nutritional specialty products, respectively, which support immune function and gut health in ruminants and as feed-efficient alternatives to traditional . The 2015 purchase of the Western Yeast business introduced Cellerate Yeast Solutions, yeast-based products aiding intestinal integrity and pathogen resistance in food animals. In 2016, the acquisition of Laboratories added and manufacturing for and other species, strengthening preventive disease management. Entry into began in 2014 with the assets of AquaVet Ltd., followed by the 2018 acquisition of KoVax's fish portfolio, expanding solutions for bacterial and viral threats in and farming. Recent developments reflect adaptation to antibiotic stewardship trends, with emphasis on , direct-fed microbials, and nutritional specialties like Magni-Phi, which promote balance and reduce reliance on s in U.S. and emerging markets. The October 2024 completion of the $350 million acquisition of Inc.'s medicated feed additives and water-soluble products portfolio added 37 product lines and six manufacturing sites, further fortifying Phibro's global reach in , , and disease mitigation across over 80 countries. These moves have prioritized scalable, evidence-based interventions for productivity while navigating restrictions like the U.S. FDA's 2017 guidance on judicious use.

Products and Services

Animal Health Solutions

Phibro Animal Health provides medicated feed additives focused on therapeutic interventions against bacterial and protozoal pathogens in production animals. Antibacterials such as Mecadox® (carbadox), a Type A medicated article, target bacterial enteritis caused by Salmonella choleraesuis (necrotic enteritis) and dysentery associated with Brachyspira hyodysenteriae. These are incorporated into feeds at concentrations of 10-55 grams per ton to control clinical disease, with field data showing significant reductions in morbidity and mortality from enteritis outbreaks. Anticoccidials, including ionophores like Coxistac® (salinomycin sodium), address in caused by such as E. tenella and E. necatrix. Administered in feeds at 40-60 , these compounds disrupt parasite transport, preventing intestinal lesions and oocyst shedding that precipitate flock-wide declines. Controlled studies confirm their role in minimizing production losses, including lowered mortality from severe infections, by sustaining gut integrity and feed intake. Distribution occurs primarily through licensed feed mills, where premixes are blended into complete rations under veterinary oversight to align with approved indications for disease control. Usage guidelines stress targeted application during at-risk periods, such as post-weaning in or starter phases in broilers, to preserve therapeutic efficacy against verified pathogens without reliance on subtherapeutic dosing.

Mineral Nutrition Offerings

Phibro Animal Health Corporation provides a range of non-pharmaceutical nutrition products, primarily trace premixes and supplements, designed to correct dietary deficiencies in such as and . These offerings address variability in content of forages, which can result from regional conditions, to support metabolic functions, , and without relying on therapeutic interventions. Central to the portfolio is ™, a premium line of chelated organic trace minerals including , , and , formulated for enhanced in ruminants and monogastrics. Introduced in 2015, these products target dairy and as well as , promoting integrity, immune function, and activity essential for nutrient utilization. Complementing this, the Vistore® series delivers inorganic chloride-based trace minerals with elevated concentrations of , , and to optimize delivery efficiency and conserve ration space in high-density feeds. These value-oriented formulations suit and operations, where precise mineral balancing aids in maintaining microbial stability and overall herd performance. Phibro also offers custom premix blending services, incorporating elements like Phil-Chrome for metabolic support, certified under Dairy Quality Assurance standards to ensure homogeneity and efficacy. By fortifying diets with bioavailable traces, these products facilitate improved feed efficiency and lower incidence of deficiency-related disorders, as evidenced by on supplementation showing gains in weight-to-feed ratios and reduced supplemental needs in production animals.

Vaccines and Diagnostics

Phibro Animal Health Corporation specializes in autogenous vaccines, which are customized inactivated biologics formulated using pathogens isolated from a specific herd or flock to address prevalent bacterial and viral threats. These vaccines target diseases like Newcastle disease in and porcine reproductive and respiratory syndrome (PRRS) in , promoting herd-level immunity through tailored immune responses against local strains. While potency and efficacy of autogenous biologics are not formally established under standard regulatory trials due to their customized nature, they are deployed to minimize disease outbreaks and associated production losses. In poultry operations, Phibro offers vaccines such as V.H. + H-120, a live attenuated bivalent containing the V.H. of Newcastle disease virus and H-120 of infectious bronchitis virus, administered via coarse spray or drinking water to broilers, , and layers for primary protection. Autogenous formulations extend coverage to multiple viral and bacterial pathogens, including customized options for reovirus variants, integrated into programs that prime flocks against evolving field challenges. These approaches support early intervention, potentially lowering the incidence of secondary bacterial infections and reducing interventions by preventing viral-driven . For , Phibro's MJPRRS autogenous provide herd-specific protection against PRRS , administered as inactivated injections to sows and wean-to-finish pigs to reproductive failures, respiratory issues, and mortality. Broader autogenous address a spectrum of viral challenges, including those akin to type 2 through multivalent combinations, aiding in sustained herd health amid strain variability. efficacy in field settings correlates with decreased and outbreak frequency, facilitating reduced reliance during PRRS-related events by bolstering innate and adaptive immunity. Phibro's diagnostics complement strategies via an in-house that isolates and identifies from clinical samples, enabling precise autogenous . Services include proprietary media, sampling kits, and custom development for rapid detection, integrated into comprehensive health management protocols for proactive monitoring. This diagnostic backbone supports early outbreak identification, allowing targeted to enhance and limit disease amplification in intensive production systems.

Regulatory and Legal Matters

FDA Interactions and Approvals

Phibro Animal Health Corporation has secured multiple FDA approvals for ionophores such as lasalocid sodium, marketed as Bovatec for and Avatec for , under longstanding New Animal Drug Applications (NADAs) that permit their use in medicated feeds to enhance feed efficiency and control . These approvals, originally established in the , rely on demonstrated efficacy and safety data, including tolerance levels for residues in edible tissues, and align with the Animal Medicinal Drug Use Clarification Act (AMDUCA) of 1994, which authorizes veterinarians to prescribe extra-label uses of approved drugs when necessary to address animal needs under a valid veterinarian-client-patient relationship. Similarly, Phibro's approvals for antibiotics like oxytetracycline in feed applications have been maintained through compliance with FDA residue monitoring standards. Following FDA Guidance for Industry #213 issued in December 2013, which initiated a transition toward veterinary oversight for medically important antimicrobials in feed to promote judicious use, Phibro adapted its product portfolio to the Veterinary Feed Directive (VFD) regulations finalized in 2015 and effective June 2017. This included updating labeling and distribution protocols for VFD-designated drugs, such as certain formulations of oxytetracycline (Terramycin), to require a veterinarian's authorization via a VFD order, limiting use to specified species, durations, and conditions while prohibiting extra-label applications in feed. Phibro's non-VFD products, when used as sole medications, continued availability without such restrictions, reflecting targeted regulatory adjustments based on drug class and risk assessments rather than across-the-board prohibitions. Phibro has pursued ongoing label expansions supported by residue depletion studies and pharmacokinetic data, as evidenced by FDA approvals for combination feeds, such as virginiamycin with on April 7, 2025, under , which incorporated safety evaluations confirming no adverse residue impacts. A notable recent approval occurred on November 14, 2024, for Paqflor (florfenicol premix), the first generic for controlling bacterial diseases in freshwater-reared salmonids, , and other finfish, granted after review of , trials, and safety data establishing safe withdrawal periods. These decisions underscore FDA's reliance on empirical residue determinations and analyses over precautionary policy measures.

Carbadox Controversy and Litigation

On November 7, 2023, the U.S. (FDA) issued a final order revoking the approved regulatory method for detecting residues of carbadox—a marketed by Phibro Animal Health Corporation under the brand Mecadox® for use in feed to promote growth and control bacterial . The FDA determined that the method, approved in 1998, was inadequate because it failed to establish a validated between the marker residue (carbadox itself) and total residues of toxicological concern, including carcinogenic metabolites such as desoxycarbadox and semicarbadox, thereby preventing reliable monitoring of potential human exposure risks from animal tissues. In parallel, the FDA proposed withdrawing approval for carbadox's new animal drug applications, citing the absence of a compliant method under the Delaney Clause of the Federal Food, Drug, and Cosmetic Act, which prohibits carcinogenic residues in food. Phibro contested the revocation, asserting that it undermined over four decades of empirical , including residue depletion studies demonstrating low detectable levels of carbadox and its metabolites in tissues at approved doses, with risks far below thresholds of concern. On January 5, 2024, Phibro filed suit in the U.S. District Court for the District of Columbia against FDA Commissioner Robert M. Califf, alleging the agency's actions were arbitrary, capricious, and procedurally flawed under the , as they bypassed required evidentiary hearings and ignored prior validations without new evidence of harm. The company argued the revocation effectively halted commercial viability of Mecadox absent an alternative method, despite real-world monitoring showing compliance and negligible carcinogenic risks. On November 5, 2024, U.S. District Judge John D. Bates dismissed the case as unripe for , ruling that the revocation order alone did not constitute a final action causing concrete injury, since FDA had not yet formally withdrawn approval or enforced , leaving Phibro opportunity for administrative remedies like submitting a new . Phibro indicated intent to appeal, maintaining that the decision perpetuates uncertainty for swine producers reliant on carbadox for disease management, while FDA emphasized the need for validation to ensure safeguards against unmonitored carcinogens. Absent resolution or a replacement , the controversy raises potential for market discontinuation of carbadox, though Phibro cites ongoing residue studies affirming safety margins exceeding regulatory limits by orders of magnitude.

Controversies and Criticisms

Antibiotic Use and Resistance Debates

Phibro Animal Health's products, primarily polyether ionophores such as monensin and lasalocid used as coccidiostats in and ruminants, have sparked debates over their role in (AMR). Proponents argue that these agents provide targeted control of protozoan pathogens like species, thereby preventing outbreaks that would otherwise necessitate broader-spectrum therapeutic , potentially reducing overall exposure in . Field studies, including trials comparing ionophores to classical , demonstrate that ionophores maintain diversity without the associated with broad-spectrum agents, limiting selective pressure for in commensal bacteria. Ionophores' narrow spectrum—primarily affecting ion transport in susceptible eukaryotes and select —contrasts with human medicines like beta-lactams or fluoroquinolones, showing minimal evidence of cross-resistance to clinically important pathogens in most empirical data. The World Health Organization's List of Medically Important excludes ionophores, classifying non-human-specific classes used in as lower-risk for human transmission compared to critically important agents like third-generation cephalosporins. U.S. reports indicate that while medically important antimicrobials for food animals accounted for significant sales volumes in 2023 (with a 2% decline from prior years), ionophores fall outside this category and constitute a small fraction of total antimicrobial tonnage, emphasizing their specialized role over growth promotion. Critics, including advocacy organizations like the FAIRR Initiative, contend that even subtherapeutic or preventive uses in foster environmental reservoirs of genes, potentially disseminating via chains or effluents, regardless of . These groups highlight emerging studies linking exposure to co-selection of in pathogens like , arguing that any agricultural antimicrobial contributes to the global crisis amid rising livestock biomass. However, such claims often extrapolate from or lab models without robust causal links to human infections, as longitudinal data from the FDA and CDC show no direct between ionophore use and elevated resistance rates in key human Salmonella or Campylobacter isolates. In response to stewardship pressures, Phibro has invested in non-antibiotic alternatives, including direct-fed microbials like Bacillus-based products (e.g., MicroLife Prime) that enhance gut and , reducing reliance on ionophores in antibiotic-free production systems. Company trials report these sustain performance metrics comparable to ionophore-supplemented feeds, supporting a transition that aligns with FDA guidance on judicious use while preserving and productivity. This shift underscores empirical trade-offs: unchecked can amplify secondary bacterial infections requiring therapeutic antibiotics, whereas targeted ionophores mitigate such cascades without proven widespread human health impacts.

Environmental and Ethical Concerns

Phibro Animal Health Corporation's subsidiary Phibro-Tech, Inc., has faced environmental scrutiny primarily related to groundwater contamination at its facility, part of the Omega Chemical Site. In 1995, the U.S. Environmental Protection Agency (EPA) and California Department of Toxic Substances Control approved a remediation plan requiring Phibro-Tech to pump and treat contaminated groundwater to remove pollutants including , , and volatile organic compounds. The EPA designated Phibro-Tech as a potentially responsible party (PRP) in 2012 due to historical operations contributing to commingled plume migration, with ongoing investigations and monitoring. Phibro maintains reserves for such remediation, totaling approximately $7 million as of June 30, 2016, and reports material compliance with environmental laws, though future liabilities remain uncertain pending regulatory changes or new findings. Broader concerns involve potential pollution from manufacturing , particularly residues discharged from production facilities, a highlighted in analyses of the animal health sector. Assessments indicate Phibro provides no relevant on policies to manage such residues in , contrasting with calls for enhanced to prevent environmental dissemination. Phibro has responded through initiatives emphasizing emission reductions and sustainable practices, including compliance with EPA permits and capital expenditures of $3 million in fiscal for environmental controls. Localized incidents, such as permit renewal delays and incomplete contamination characterization noted by California's Department of Toxic Substances Control in 2023, underscore persistent oversight challenges at legacy sites. Ethical critiques often link Phibro's products to intensive farming, arguing they facilitate high-density operations with potential implications, though direct causal evidence tying Phibro's offerings to systemic ethical lapses is limited. Counterarguments emphasize that animal health solutions promote efficient resource use, with healthier requiring less land and feed per unit of output, thereby mitigating emissions intensity amid rising global protein demand. Environmental advocacy groups, such as , advocate stricter permitting to address historical non-compliance, viewing lax renewals as enabling ongoing risks. In contrast, agricultural analyses highlight net benefits, positing that such interventions support without proportional environmental escalation, prioritizing empirical productivity data over generalized opposition to intensification.

Impact and Achievements

Contributions to Agriculture and Food Security

Phibro Animal Health's vaccines and anticoccidial programs have facilitated the control of coccidiosis in poultry, a parasitic disease causing global economic losses exceeding $3 billion annually due to impaired growth, reduced feed efficiency, and mortality. These interventions target both clinical infections, estimated to account for 20% of losses, and subclinical cases comprising 80%, with prevention strategies proving cost-effective relative to curative measures. By enabling immunity development through live vaccines that peak oocyst cycling around day 14 of age, Phibro's offerings enhance flock resilience and productivity, directly supporting stable protein output in intensive farming systems. In regions like , Phibro's initiatives, such as the Cattle Raising Insight project, provide farmers with tools to boost efficiency and output, addressing challenges in amid growing demand. These efforts extend mineral nutrition and health solutions to diverse operations, optimizing feed utilization and reducing waste to conserve resources while scaling affordable animal-derived foods. Such programs align with broader goals of enhancing by improving and yield without expanding land use, particularly in areas reliant on for . Phibro's research emphasizes nutritional specialties and as viable alternatives to traditional antibiotics, fostering while preserving performance metrics like growth rates and disease resistance. Investments in these areas, including customized mineral balances for regional diets, enable producers to maintain efficacy amid regulatory pressures, thereby sustaining long-term agricultural viability and global reliability.

Financial Performance and Market Position

Phibro Animal Health Corporation completed its on April 16, 2014, issuing 14,657,200 shares of Class A at $15 per share, raising net proceeds of approximately $176.5 million after underwriting discounts, which were primarily used to repay and support operational expansion. Post-IPO, the company has demonstrated revenue growth, with net sales reaching $977.9 million for the ended , 2023, increasing to $1.018 billion in fiscal 2024 and $1.296 billion in fiscal 2025, reflecting a of about 15% over this period driven by acquisitions and segment expansion. The Animal Health segment accounted for roughly 74% of total net sales in fiscal 2025, generating $962.8 million, primarily from medicated feed additives (MFAs) such as ionophores, , and for including , , and . This segment's performance underscores Phibro's specialization in anticoccidials and feed efficiency products, where it maintains a leading market share alongside competitors like Animal Health and , though it trails these larger players in overall scale—Zoetis reported $8.5 billion in 2023 revenues compared to Phibro's under $1 billion at the time. Phibro's position benefits from a focus on essential, non-discretionary products for food animal production, with diversification into mineral nutrition (about 20% of sales) and /diagnostics providing buffers against U.S. regulatory constraints on antibiotic use. In fiscal fourth quarter 2024 (ended June 30, 2024), Phibro reported net sales of $273.2 million, up 7% year-over-year, with Animal Health sales rising 8% to $191.5 million despite persistent challenges in the U.S. antibiotics submarket due to heightened veterinary oversight and reduced usage trends; these were offset by stronger performance in specialties and markets, particularly in and . The company's adjusted EBITDA margin improved amid cost controls, positioning it as a mid-tier player resilient to sector headwinds like debates, with a of around $600 million as of late 2025 reflecting steady but not explosive valuation multiples relative to peers.

References

  1. [1]
    Phibro LLC - Global Pure Play Green Commodity Company
    Phibro Is a Global Pure Play Green Commodity Company, Focused on Innovative Assets, Development, Acquisitions, Optimization, and Contract Structuring.
  2. [2]
    History - Phibro LLC Commodities merchant investing
    Founded in 1901 by Julius & Oscar Philipp, this prototypical commodities trading house has developed an entrepreneurial approach to capitalizing on physical ...
  3. [3]
    FACTBOX: A history of Citi's Phibro unit - Reuters
    Oct 9, 2009 · * Phibro was founded in 1914, originally as Philipp Brothers. In the 1960s it became a part of Engelhard Minerals & Chemicals Corp, but it was ...
  4. [4]
    Legendary Trading Firm Phibro Gets New Life After Purchase
    Jan 27, 2016 · Arab Embargo. Founded in 1901 as Phillip Brothers, Phibro traded commodities such as metals and chemicals. In 1973, the firm dove into the crude ...
  5. [5]
    https://www.wsj.com/articles/phibro-to-shut-down-u-s-business-1418181931
  6. [6]
    phibro animal health corporation - SEC.gov
    Phibro Animal Health Corporation is one of the leading animal health companies in the world and is dedicated to helping meet the growing demand for animal ...
  7. [7]
    Phibro Animal Health Corporation Prices Its Initial Public Offering
    Apr 11, 2014 · The gross proceeds from the offering will be approximately $125 million for the Company and approximately $66 million for 3i Group. In addition, ...Missing: founded | Show results with:founded
  8. [8]
    Phibro Animal Health 2025 Company Profile - PitchBook
    Phibro Animal Health ; Market Cap $1.61B ; Average Volume 331K ; EPS $1.19 ; HQ Location. Teaneck, NJ ; Employees. 2,475 as of 2025.
  9. [9]
    PAHC.OQ - Phibro Animal Health Corp - Reuters
    Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products ...
  10. [10]
    Company Phibro Animal Health Corporation - MarketScreener
    It markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. It has three segments: Animal Health, Mineral Nutrition ...
  11. [11]
    [PDF] For People, Animals and the Planet
    At Phibro, it's the dynamic connections between people, animals and the planet that inspire our teams around the globe to advance our Purpose: Optimize animal ...
  12. [12]
    Phibro Animal Health Corporation_June 30, 2025 - SEC.gov
    Animal Health, Mineral Nutrition ... (“Phibro-Tech”) business units. ​. 15. Table of Contents. Sales and ...
  13. [13]
    Press Release Details - Phibro Animal Health Corporation
    Nov 7, 2023 · Mecadox (carbadox) has been approved and sold in the United States for more than 50 years and is a widely used treatment for controlling ...
  14. [14]
    Phibro Animal Health Corporation - Overview
    We sell animal health and mineral nutrition products either directly to integrated poultry, swine and cattle producers or through animal feed manufacturers, ...Missing: core | Show results with:core
  15. [15]
    Mineral Nutrition - PAHC - Phibro Animal Health Corporation
    Our DQA certified premium mineral nutrition products include GemStone, Vistore and Phil-Chrome and are designed to ensure optimal animal nutrition.
  16. [16]
    [PDF] Phibro Animal Health Corporation
    Sep 1, 2023 · Phibro Animal Health, established in 1946, is a leader in animal health, selling ~730 product lines in >80 countries, with 3 business segments.
  17. [17]
    Phibro Animal Health Corporation (PAHC) Company Profile & Facts
    It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through ...<|separator|>
  18. [18]
    Ludwig Jesselson - Immigrant Entrepreneurship
    Aug 30, 2013 · In the decades after 1945, Philipp Brothers grew to become the largest and most important metal trading company in the world.
  19. [19]
    About Us - PAHC - Phibro Animal Health Corporation
    PhibroChem® was originally introduced as Philipp Brothers Chemicals in 1946. However, the company's roots trace back to the early 1900s when our founder ...Missing: history | Show results with:history
  20. [20]
    Philipp Brothers Collection - Center for Jewish History
    Historical Note​​ The origins of the metal dealer company Philipp Brothers go back to Hamburg, Germany, 1901. From very small beginnings the company developed ...Missing: Chemicals 1946
  21. [21]
    Philipp Brothers Chemicals, Inc. (n. Y.), Appellant, v. Commissioner ...
    Their operations did not include any repackaging, processing, or manufacturing of chemicals. Of the domestic corporations, only the Pennsylvania and ...Missing: early 1946-1973
  22. [22]
    History - PAHC - Phibro Animal Health Corporation
    Here you can learn about our founding in 1946 as Phillipp Brothers Chemicals, Inc. through our name change in 2003 to all of our acquisitions through 2019.
  23. [23]
    Philipp Brothers Chemicals, Inc.(NY) v. CIR - vLex Case Law
    Their operations did not include any repackaging, processing, or manufacturing of chemicals.Of the domestic corporations, only the Pennsylvania and Maryland ...Missing: early | Show results with:early
  24. [24]
    [PDF] PAHN_Brochure_12.2.19.pdf - Phibro Animal Health Corporation
    Formed as. Philipp Brothers. Chemicals, Inc. 1974. Acquired Koffolk, an Israeli animal nutrition business. 1994. Began amprolium manufacturing. 2000. Acquired ...Missing: history | Show results with:history
  25. [25]
    Board of Directors - Person Details - Phibro Animal Health Corporation
    In 2008, he led the acquisition of Abic Biological Laboratories from Teva, and in 2009, he was appointed the Managing Director of our operations in Israel.
  26. [26]
    Phibro Animal Health Corporation to Acquire Business of MVP ...
    Jan 12, 2016 · Phibro Animal Health Corporation to Acquire Business of MVP Laboratories, Inc., an Animal Vaccine and Adjuvant Manufacturer and Marketer.Missing: Vetech | Show results with:Vetech
  27. [27]
    Press Release Details - Phibro Animal Health Corporation
    Jan 20, 2014 · Phibro Animal Health Corporation announces its Phibro Aquaculture Business Unit, led by Dr. Ra'anan Ariav, and the Acquisition of the Assets of ...Missing: expansions | Show results with:expansions
  28. [28]
    Aquaculture Acquisition to Create Vaccine Innovation Powerhouse
    Dec 6, 2018 · Phibro acquired KoVax's fish vaccine business, strengthening its position in fish vaccine innovation and expanding its aquaculture product ...
  29. [29]
    Magni-Phi - Phibro Animal Health Corporation
    Magni-Phi® nutritional specialty products have consistently demonstrated improved intestinal health and immune response as a natural alternative to antibiotics
  30. [30]
    Direct-Fed Microbials - DFM - Phibro Animal Health Corporation
    Phibro offers several direct-fed microbial solutions designed to help improve your livestock production efficiency and performance. POULTRY PRODUCTS. POULTRY ...
  31. [31]
    Phibro Animal Health Corporation Completes Acquisition of Zoetis ...
    Oct 31, 2024 · The acquisition includes a product portfolio with more than 37 product lines sold across approximately 80 countries, six manufacturing sites ...<|control11|><|separator|>
  32. [32]
    Mecadox® 10 (carbadox) TYPE A MEDICATED ARTICLE - DailyMed
    Indications for Use: Control of swine dysentery (vibrionic dysentery, bloody scours or hemorrhagic dysentery); control of bacterial swine enteritis ...
  33. [33]
    [PDF] Mecadox®10 - Phibro Animal Health Corporation
    Control of bacterial swine enteritis (salmonellosis or necrotic enteritis caused by Salmonella choleraesuis). Increased rate of weight gain and improved feed.
  34. [34]
    [PDF] Improves pig performance in a wide range of health and growing ...
    Morbidity and mortality rates caused by bacterial enteritis. (Salmonella choleraesuis) were also significantly reduced with Mecadox use. Summary: Example ...
  35. [35]
    Coxistac - Anticoccidial - Phibro Animal Health Corporation
    PRODUCT FEATURES: The oldest and most recognized anticoccidial brand; No negative interaction with nutrient, feed or water intake; Consistent results in all ...Missing: therapeutic | Show results with:therapeutic
  36. [36]
    [PDF] Prevention and control of coccidiosis in broilers.
    For more than 25 years, Coxistac® 12% (Salinomycin sodium) is being used all over the world for the prevention and control of coccidiosis in broilers. COXISTAC ...
  37. [37]
    120g/kg SALINOMYCIN SODIUM - Phibro Animal Health Corporation
    Coxistac enables you to reach market weight faster with reduced losses from coccidiosis. This means more efficient and profitable production. For enhancing ...Missing: mortality | Show results with:mortality
  38. [38]
    Products - PAHC - Phibro Animal Health Corporation
    Our copper, manganese and zinc formulas feature high metal content to ensure optimal mineral presence and preserve critical ration space.
  39. [39]
    Phibro Anticoccidial Solutions - PAHC
    We offer a comprehensive anticoccidial portfolio of products that have been used in billions of broilers around the world. Manufactured under strict internal ...
  40. [40]
    Phibro Animal Health Corporation Introduces GemStoneTM Organic ...
    Feb 9, 2015 · Chelated organic trace minerals help promote health and productivity for dairy and beef cattle, poultry, swine, aquaculture and companion ...
  41. [41]
    Viewing Products for - Phibro Animal Health Corporation
    The Vistore® portfolio of products is Phibro's chloride mineral option of value-driven trace mineral offerings. Our copper, manganese and zinc formulas feature ...
  42. [42]
    [PDF] In the trace minerals marketplace, quality, service, and performance ...
    Rest assured, Phibro will produce a homogenous trace mineral premix that delivers the mineral nutrition you require and expect in every bite for the animals ...Missing: offerings cattle swine
  43. [43]
    Feeding low dietary levels of organic trace minerals improves broiler ...
    Feeding low dietary levels of organic trace minerals improves broiler performance and reduces excretion of minerals in litter · Authors · Affiliations.Missing: studies Phibro interventions
  44. [44]
    Tailor-Made Autogenous Vaccines - Phibro Animal Health Corporation
    Phibro Animal Health Corporation's Tailor-Made autogenous vaccines help you and your operation combat a variety bacteria and viruses that are harmful to your ...
  45. [45]
    [PDF] V.H. + H-120 - Phibro Animal Health Corporation
    Vaccine strains. V.H. + H-120 is a live attenuated, freeze dried virus vaccine for Newcastle Disease and Infectious Bronchitis, developed from the V.H. ...Missing: swine porcine circovirus
  46. [46]
    Phibro introduces autogenous vaccines for poultry reovirus
    *Potency and efficacy have not been established for autogenous biologics. Phibro is a diversified global developer, manufacturer and marketer of a broad ...
  47. [47]
    Poultry - PAHC - Phibro Animal Health Corporation
    Our poultry products are designed for farmers to protect the health of their animals by providing Medicated Feed Additives, Vaccines, ...
  48. [48]
    MJPRRS® Autogenous Vaccines - Phibro Animal Health Corporation
    MJPRRS® Autogenous Vaccines* are herd-specific inactivated vaccines for the prevention of losses associated with PRRS in sows and wean-to-finish pigs.
  49. [49]
    Swine - Autogenous Vaccine - Phibro Animal Health Corporation
    With our swine autogenous vaccines we can help you manage your herd against a variety of bacterial and viral challenges. Our swine autogenous vaccines are made ...Missing: circovirus | Show results with:circovirus
  50. [50]
    MJPRRS Vaccine - Phibro Pro
    The MJPRRS vaccine is a custom-made vaccine that helps to minimize production losses and assist operations in surviving continued PRRS challenges.Missing: PCV | Show results with:PCV
  51. [51]
    Diagnostics and R&D - Phibro Animal Health Corporation
    Diagnostics are the backbone of clinical medicine. Phibro offers a well-regarded diagnostics lab and the R&D capabilities necessary for autogenous vaccine ...
  52. [52]
    [PDF] autogenous vaccines - Phibro Animal Health Corporation
    Tailor-Made® autogenous vaccines – an aid in protecting your herd against a wide range of bacteria and viruses. Tailor-Made vaccines have the ability to fit ...
  53. [53]
    Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) - FDA
    Oct 24, 2024 · AMDUCA permits veterinarians to prescribe extralabel uses of certain approved new animal drugs and approved human drugs for animals under ...
  54. [54]
    List of Approved Medically Important Antimicrobial Drugs ... - FDA
    May 22, 2024 · Phibro Animal Health Corp. Oxytetracycline. Pioneer Type A medicated article, 010-918, Elanco US, Inc. Hygromycin B. Pioneer Type A medicated ...
  55. [55]
    [PDF] Terramycin (oxtetracycline) Veterinary Feed Directive for use in ...
    This VFD only authorizes the use of the VFD drug(s) cited in this order and is not intended to authorize the use of such drug(s) in combination with any other ...Missing: compliance | Show results with:compliance
  56. [56]
    Withdrawal of Approval of New Animal Drug Applications; Change of ...
    Aug 22, 2025 · Original approval, 558.635. April 7, 2025, 141-588, Phibro Animal Health Corp. (066104), V-MAX (virginiamycin) and RUMENSIN (monensin) Type A ...
  57. [57]
    FDA Approves First Generic Florfenicol for Controlling Mortality in ...
    Nov 14, 2024 · The US Food and Drug Administration approved Paqflor (florfenicol), the first generic florfenicol drug for controlling mortality in certain species of ...Missing: ionophores | Show results with:ionophores
  58. [58]
    Phibro Animal Health Corp.; Carbadox in Medicated Swine Feed
    Nov 7, 2023 · The Food and Drug Administration (FDA) is issuing a final order to revoke the approved method for detecting residues of carbadox, a carcinogenic new animal ...
  59. [59]
    Questions and Answers Regarding Carbadox - FDA
    Apr 24, 2024 · Carbadox is an animal drug used in swine (hogs and pigs) for production purposes (eg, increased rate of weight gain and improved feed efficiency) and ...
  60. [60]
    Phibro Animal Health Corp.; Proposal To Withdraw Approval of New ...
    Nov 7, 2023 · FDA-2023-N-4742 for “Phibro Animal Health Corp.; Proposal to Withdraw Approval of New Animal Drug Applications for Carbadox in Medicated Swine ...
  61. [61]
    From the Porcine to the Ridiculous to the Court of Appeals: Phibro's ...
    Nov 5, 2024 · More specifically, FDA rescinded approval of a “regulatory method” that Phibro used to establish that carbadox is safe and effective. Under that ...
  62. [62]
    Lawsuit over FDA's swine drug cancer concerns dismissed as 'unripe'
    Nov 6, 2024 · U.S. District Judge John Bates in Washington, D.C., has dismissed a lawsuit the Phibro animal health company filed earlier this year against the ...
  63. [63]
    Lawsuit over FDA's regulatory approval process for carbadox ...
    Nov 7, 2024 · ... swine dysentery and bacterial swine enteritis, carbadox has been shown to be carcinogenic in laboratory animals. There are three approved ...
  64. [64]
    Differential Impact of Subtherapeutic Antibiotics and Ionophores on ...
    Aug 22, 2019 · In this study, male Cobb broiler chickens were supplemented for 14 days with or without one of five commonly used AGPs including three classical antibiotics.
  65. [65]
    [PDF] FEATURE - Phibro Animal Health Corporation
    Aug 31, 2023 · Also, slow resistance development: there is a narrow safety margin (10-20% for all ionophores)". After describing the mode of action for ...
  66. [66]
    WHO publishes the WHO Medically Important Antimicrobials List for ...
    Feb 8, 2024 · The WHO list of medically important antimicrobials for human medicine (WHO MIA List) is a risk management tool that can be used to support decision-making.
  67. [67]
    2023 Summary Report On Antimicrobials Sold or Distributed for Use ...
    Oct 10, 2024 · This is the 2023 FDA summary report on antimicrobials for food-producing animals, with data updated annually. Data is not confidential.
  68. [68]
    $$47-Billion Animal Health Sector Fuelling Irresponsible ...
    Jul 22, 2021 · The growing threat of AMR is largely due to the inappropriate overuse of antimicrobials, the majority of which are currently used in livestock ...
  69. [69]
    Staphylococcus aureus mutants resistant to the feed-additive ...
    Jan 12, 2024 · In this study, we demonstrate that exposure to the ionophore monensin can select for resistant mutants in the human and animal pathogen ...<|separator|>
  70. [70]
    [PDF] MicroLife Prime - Phibro Animal Health Corporation
    MicroLife Prime contains four active and specifically selected Bacillus strains to promote poultry health.
  71. [71]
    CAL/EPA AND U.S. EPA ANNOUNCE CLEANUP IN SANTA FE ...
    Jul 6, 1995 · Department of Toxic Substances Control. The plan calls for Phibro-Tech to pump and treat groundwater to remove contaminants, including cadmium, ...
  72. [72]
    [PDF] Phibro Animal Health Corporation
    Feb 8, 2023 · The EPA has named Phibro-Tech and certain other subsidiaries of PAHC as potentially responsible parties (“PRPs”) due to groundwater ...
  73. [73]
    t1602037_10k - none - 10.1290128s - SEC.gov
    The EPA has named Phibro-Tech and certain other subsidiaries of PAHC as PRPs due to groundwater contamination from Phibro-Tech's Santa Fe Springs facility that ...<|separator|>
  74. [74]
    Phibro Animal Health Corporation - FAIRR Initiative
    May 22, 2024 · C.1.1. Phibro offers a selection of products that could potentially reduce the need for antibiotic use, such as vaccines and nutritional ...
  75. [75]
    [PDF] justice and phibro-tech's permit renewal - Earthjustice
    Mar 18, 2024 · In 2023, DTSC noted that in certain areas of the site “it is unclear whether contamination has been fully characterized due to an inability to ...
  76. [76]
    [PDF] For People, Animals and the Planet
    Jun 30, 2022 · Phibro serves in various leadership roles, directly contributing to HealthforAnimals resources leveraged by the broader animal health sector and ...
  77. [77]
    Effects on the Environment - Phibroconsumer.com
    Sick animals have a larger environmental impact, while healthy animals use fewer natural resources · Antibiotics help reduce the consumption of natural resources.
  78. [78]
    [PDF] for the implementation of an anticoccidial program.
    This allows for effective coccidiosis control with a lower risk of side effects of the drugs. Synergistic combinations. Page 8. the infection pressure. Knowing ...Missing: Coxistac | Show results with:Coxistac<|separator|>
  79. [79]
    [PDF] Technical Bulletin - Phibro Animal Health Corporation
    Coccidiosis vaccines have been shown to perform optimally when oocyst production peaks around 14 days of age and then declines as birds develop immunity from ...Missing: losses | Show results with:losses
  80. [80]
    Sustainability Actions Report - HealthforAnimals - Health for Animals
    Phibro Animal Health's 'Cattle Raising Insight' project in Brazil helps farmers generate higher productivity and efficiency. Zoetis' A.L.P.H.A. project provides ...
  81. [81]
    Vision, Purpose, Values - Phibro Animal Health Corporation
    Values · Keep animals healthy. Phibro has consistently contributed to a healthy, affordable food supply by helping farmers responsibly care for their animals.
  82. [82]
    Phibro at Morgan Stanley Conference: Strategic Growth and ...
    Sep 9, 2025 · Strategic investments are being made in vaccines, nutritional specialties, and companion animal markets. Phibro achieved its net leverage ratio ...
  83. [83]
    [PDF] Environmental, Social, Governance
    Approximately 780 product lines sold in more than 80 countries spanning three business segments: Animal Health, Mineral Nutrition and. Performance Products.
  84. [84]
    [PDF] PHIBRO ANIMAL HEALTH CORP - AnnualReports.com
    Sep 18, 2014 · On April 16, 2014, we completed the initial public offering (“IPO”) of 14,657,200 shares of Class A common stock (including the exercise of ...
  85. [85]
    Phibro Animal Health shares rise 10 percent in debut | Reuters
    The animal health product maker's IPO raised about $176.5 million from the offering of 11.8 million class A shares, which were priced at $15 per share, ...
  86. [86]
    Global Top 10 Animal Health Companies in 2024 - Proclinical
    In 2023, the company recorded revenues of US$8.5 billion, an increase of a steady 6% growth compared to 2022, driven by a stellar performance for their ...
  87. [87]
    Phibro Animal Health Revenue 2012-2025 | PAHC - Macrotrends
    Phibro Animal Health revenue from 2012 to 2025. Revenue can be defined ... 2024-09-30, $1.047B. 2024-06-30, $1.018B. 2024-03-31, $1B. 2023-12-31, $0.982B. 2023 ...
  88. [88]
    Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal ...
    Aug 27, 2025 · Net sales of $1,296.2 million, an increase of $278.5 million, or 27% · Net income of $48.3 million, an increase of $45.8 million · Diluted ...Missing: divisions | Show results with:divisions
  89. [89]
    Phibro Q4 2025 slides: Revenue surges 39%, FY2026 outlook strong
    Aug 28, 2025 · The Animal Health segment was the primary driver of full-year growth, with sales increasing 36% to $962.8 million and adjusted EBITDA rising 53% ...
  90. [90]
    Ionophores Market Research Report 2033 - Dataintelo
    Major companies operating in the ionophores market include Elanco Animal Health, Zoetis Inc., Phibro Animal Health Corporation, Huvepharma, and Kemin Industries ...Product Type Analysis · Application Analysis · Competitor Outlook<|separator|>
  91. [91]
    https://www.expertmarketresearch.com/client-sectors/animal-health-nutrition
  92. [92]
    Press Release Details - Phibro Animal Health Corporation
    Aug 28, 2024 · Net sales of $273.2 million for the three months ended June 30, 2024 increased $18.1 million, or 7%, as compared to the three months ended June 30, 2023.
  93. [93]
    Phibro Animal Health Corp (PAHC) Q4 2024 Earnings Call Highlights
    Oct 9, 2024 · Consolidated Net Sales (Q4): $273.2 million, a 7% increase year-over-year. Animal Health Segment Sales (Q4): $191.5 million, an 8% increase.Missing: FY2024 | Show results with:FY2024
  94. [94]
    Phibro beats Q4 estimates but cites weakness in U.S. antibiotics ...
    Aug 30, 2016 · Phibro beats Q4 estimates but cites weakness in U.S. antibiotics ... Phibro Animal Health is facing pressure from the FDA over its pig antibiotic.